- Home
- NRIM vs RGNX Comparison
NRIM vs RGNX Comparison
Compare NRIM & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRIM | RGNX |
|---|---|---|
| Founded | 1990 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 655.9M | 761.9M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | NRIM | RGNX |
|---|---|---|
| Price | $24.11 | $13.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $30.38 |
| AVG Volume (30 Days) | 173.4K | ★ 748.5K |
| Earning Date | 01-23-2026 | 03-12-2026 |
| Dividend Yield | ★ 2.54% | N/A |
| EPS Growth | ★ 73.41 | N/A |
| EPS | ★ 2.87 | N/A |
| Revenue | ★ $208,902,000.00 | $161,318,000.00 |
| Revenue This Year | N/A | $133.58 |
| Revenue Next Year | $15.38 | $45.08 |
| P/E Ratio | $8.80 | ★ N/A |
| Revenue Growth | 37.50 | ★ 91.30 |
| 52 Week Low | $16.18 | $5.04 |
| 52 Week High | $30.82 | $16.19 |
Technical Indicators
Market Signals| Indicator | NRIM | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 33.33 | 48.26 |
| Support Level | $28.22 | $13.40 |
| Resistance Level | $30.82 | $16.19 |
| Average True Range (ATR) | 1.17 | 1.04 |
| MACD | -0.38 | -0.11 |
| Stochastic Oscillator | 7.88 | 19.72 |
Price Performance
Historical ComparisonAbout NRIM Northrim BanCorp Inc
Northrim BanCorp Inc is a bank holding company. The Company operates in three reportable segments: Community Banking, Home Mortgage Lending, and Specialty Finance. It generates maximum revenue from the Community Banking segment which offers loan and deposit products to business and consumer customers in its market areas and operates nearly 20 branches throughout Alaska.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.